June 17, 2015

Epidemiology of Anaphylaxis: Contributions From the Last 10 Years


Tejedor-Alonso MA1,2, Moro-Moro M1, Múgica-García MV3
1Allergy Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain
2Medicine and Surgery Department, Universidad Rey Juan Carlos, Alcorcón, Spain
3Allergy Service, Hospital Universitario de la Princesa, Madrid, Spain
J Investig Allergol Clin Immunol 2015; Vol. 25(3): 163-175
 
 Abstract

Knowledge of the epidemiology of anaphylaxis has improved during the last 10 years thanks to the increased number of publications with improved methodological robustness. Consequently, we better understand the distribution and frequency of anaphylaxis and the characteristics of fatal anaphylaxis.

Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study

Research article


Ming ZengZhi-Yong LiJin MaPing-Ping CaoHeng WangYong-Hua Cui and Zheng Liu*

Abstract
Background
Phenotype of chronic rhinosinusitis (CRS) may be an important determining factor of the efficacy of anti-inflammatory treatments. Although both glucocorticoids and macrolide antibiotics have been recommended for the treatment of CRS, whether they have different anti-inflammatory functions for distinct phenotypic CRS has not been completely understood. The aim of this study is to compare the anti-inflammatory effects of clarithromycin and dexamethasone on sinonasal mucosal explants from different phenotypic CRS ex vivo.

Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis

Research

Amanda L. McDonell1*Ulrich Wahn2Dirk Demuth1Catrina Richards1Charlie Hawes3Jakob Nørgaard Andreasen4and Felicia Allen-Ramey5

Abstract (provisional)
Background Allergy immunotherapy is an effective treatment for patients with allergic rhinitis whose symptoms are unresolved with pharmacotherapy. Allergy immunotherapy for grass pollen-induced allergic rhinitis is available in three modalities: subcutaneous immunotherapy and sublingual immunotherapy as a tablet or drop. This study aimed to understand trends in allergy immunotherapy prescribing and practice patterns for grass allergies in adult and paediatric patients in Germany.

CSACI position statement: epinephrine auto-injectors and children less than 15 kg

Michelle Halbrich1*Douglas P. Mack2Stuart Carr3Wade Watson4 and Harold Kim56

Abstract (provisional)
Epinephrine (adrenaline) is the treatment of choice for anaphylaxis. While other medications, including H1-antihistamines, H2-antihistamines, corticosteroids, and inhaled beta-2 agonists are often used to treat anaphylaxis in the emergency setting, none of these medications has been shown to reverse anaphylaxis. Fatal anaphylaxis is related to the delayed use of epinephrine. In community settings, epinephrine is available as an auto-injector in two doses, 0.15 mg and 0.3 mg.

June 13, 2015

Gene-Environment Interactions in Asthma: Genetic and Epigenetic Effects

 

Yonsei Med J > v.56(4); Jul 2015
Review Article  Open Access


     


Jong-Uk Lee,1 Jeong Dong Kim,1 and Choon-Sik Park2
1Department of Interdisciplinary Program in Biomedical Science Major, Soonchunhyang Graduate School, Bucheon, Korea.
2Genome Research Center and Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.

 Corresponding author: Dr. Choon-Sik Park, Genome Research Center and Division of Allergy and Respiratory Medicine, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon 420-767, Korea. Tel: 82-32-621-5105, Fax: 82-32-621-5023, Email: mdcspark@daum.net 
Abstract

Over the past three decades, a large number of genetic studies have been aimed at finding genetic variants associated with the risk of asthma, applying various genetic and genomic approaches including linkage analysis, candidate gene polymorphism studies, and genome-wide association studies (GWAS). However, contrary to general expectation, even single nucleotide polymorphisms (SNPs) discovered by GWAS failed to fully explain the heritability of asthma.

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

    Open Access

    Abstract

    Introduction In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised, monoclonal antibody that binds to and blocks interleukin-13 activity.

    June 11, 2015

    An individualized diagnostic approach based on guidelines for chronic urticaria (CU)


      Journal of the European Academy of Dermatology and Venereology
    Special Issue: An Overview of the Current Knowledge in Urticaria. Proceedings from the Global Urticaria Forum, November 2014, Prague, Czech Republic
    1. A.M. Giménez-Arnau1
    2. C. Grattan2
    3. T. Zuberbier3 and
    4. E. Toubi

    5. Abstract
      Chronic urticaria (CU), defined as the spontaneous or inducible appearance of hives, angioedema or both for 6 weeks or more, presents with a number of subtypes which all substantially impair patients’ quality of life (QoL).

    Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment

    Research

    Open Access

    Matt J Silver12Noah J Kessler3Branwen J Hennig12Paula Dominguez-Salas45Eleonora Laritsky3Maria S Baker3Cristian Coarfa6Hector Hernandez-Vargas7Jovita M Castelino8Michael N Routledge8Yun Yun Gong9,Zdenko Herceg7Yong Sun Lee10Kwanbok Lee10Sophie E Moore1112Anthony J Fulford12Andrew M Prentice12*and Robert A Waterland123*
    Abstract
    Background
    Interindividual epigenetic variation that occurs systemically must be established prior to gastrulation in the very early embryo and, because it is systemic, can be assessed in easily biopsiable tissues. We employ two independent genome-wide approaches to search for such variants.